![](https://wp-static.smartkarma.com/../assets/uploaded/2023/08/Smartkarma-Insight-Card-Square.png)
- Eisai’s 1Q Operating Income: 13.41 billion yen, beating the estimate of 10.15 billion yen.
- Eisai’s 1Q Net Income: 10.58 billion yen, exceeding the estimate of 7.4 billion yen.
- Eisai’s 1Q Net Sales: 189.03 billion yen, surpassing the estimate of 183.64 billion yen.
- Japan Pharmaceutical Business Revenue: 52.81 billion yen, higher than the estimate of 47.8 billion yen.
- Americas Pharmaceutical Business Revenue: 69.80 billion yen, above the estimate of 67.46 billion yen.
- EMEA Pharmaceutical Business Revenue: 19.50 billion yen, narrowly beating the estimate of 19.15 billion yen.
- 2025 Forecast for Operating Income: 53.50 billion yen, slightly below the estimate of 54.12 billion yen.
- 2025 Forecast for Net Income: 43.00 billion yen, under the estimate of 45.3 billion yen.
- 2025 Forecast for Net Sales: 754.00 billion yen, less than the estimate of 764.89 billion yen.
- 2025 Forecast for Dividend: 160.00 yen, on par with the estimate of 160.01 yen.
- Shares fell by 3.8% to 5,503 yen on 1.73 million shares traded.
- Analyst Ratings: 6 buys, 9 holds, 1 sell.
Eisai Co Ltd on Smartkarma
Analysts on Smartkarma, such as Tina Banerjee, have been closely monitoring Eisai Co Ltd (4523 JP) and its Alzheimer’s disease drug, Leqembi. In a recent report titled “New Competition Is Coming for Alzheimerβs Disease Drug; No Immediate Threat,” it was highlighted that despite the FDA approval of Eli Lilly’s Kisunla, Eisai is not expected to face immediate competition. The company is projected to comfortably meet its Leqembi FY25 revenue target of Β₯56.5B, with a significant portion coming from the U.S. market.
Furthermore, in another report titled “Leqembi Is Gathering Momentum; Imminent Competition May Spoil the Party,” the analysts pointed out Eisai’s ambitious revenue projections for Leqembi, aiming to reach Β₯1.6T by FY33. However, challenges lie ahead as a competitor drug is anticipated to receive FDA approval in 3Q24, potentially affecting Leqembi’s growth trajectory. The dynamic landscape of the Alzheimerβs treatment market requires careful observation of upcoming developments.
A look at Eisai Co Ltd Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 3 | |
Dividend | 4 | |
Growth | 3 | |
Resilience | 3 | |
Momentum | 3 | |
OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Looking ahead for Eisai Co Ltd, the company seems to be in a stable position based on its Smartkarma Smart Scores. With solid scores in Dividend, Growth, Resilience, and Momentum, Eisai is showing promise for the future. While the Value score could be improved, the overall outlook appears positive. Eisai Co Ltd, known for producing prescription drugs and medical equipment, has a diverse range of products sold globally. Through subsidiaries and sales agents, the company reaches markets in the US, Europe, and Asia, showcasing a strong presence in the industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars